Academic radiology · 2025
Microwave Ablation for T1N0M0 Papillary Thyroid Carcinoma Adjacent to Berry's Ligament.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ying Wei, Zhen'long Zhao, Jie Wu, Shi'liang Cao, Na Yu, Li'li Peng, Yan Li, Ming'an Yu
Аннотация
RATIONALE AND OBJECTIVES: To investigate the efficacy and safety of microwave ablation (MWA) in treating T1N0M0 papillary thyroid carcinoma (PTC) adjacent to Berry's ligament (BL).
MATERIALS AND METHODS: This retrospective study examined 141 patients who underwent MWA for BL-adjacent PTC between January 2015 and December 2023. All procedures utilized perithyroidal fascial space-based hydrodissection and standardized ablation protocols.Of the 141 patients initially enrolled, hydrodissection failed in 3 cases, who were subsequently treated with surgery. The remaining 138 patients successfully received MWA. Technical success, tumor disappearance, complications, and progression-free survival were assessed.
RESULTS: Among the 138 patients analyzed (95 women, 43 men), the median age was 39 years (IQR, 24-60 years). Technical success was achieved in all cases. During a median follow-up period of 24.4 months, complete tumor disappearance occurred in 67.3% of cases, with T1a tumors showing markedly superior outcomes compared to T1b lesions (82.1% versus 34.8%, P=0.042). Disease progression was observed in 2.9% of patients, including newly detected tumors (1.4%) and lymph node metastasis (1.4%). No local recurrence or distant metastasis was documented. The major complication was transient hoarseness, affecting 10.1% of patients, and all cases resolved spontaneously within six months. Subgroup analysis further identified T1b tumors as an independent risk factor for this complication (P = 0.027). Progression-free survival showed no significant difference between T1a and T1b classifications (P=0.633).
CONCLUSION: MWA offers an effective treatment option for selected patients with BL-adjacent T1N0M0 PTC, achieving favorable local tumor control with acceptable complication rates.
MATERIALS AND METHODS: This retrospective study examined 141 patients who underwent MWA for BL-adjacent PTC between January 2015 and December 2023. All procedures utilized perithyroidal fascial space-based hydrodissection and standardized ablation protocols.Of the 141 patients initially enrolled, hydrodissection failed in 3 cases, who were subsequently treated with surgery. The remaining 138 patients successfully received MWA. Technical success, tumor disappearance, complications, and progression-free survival were assessed.
RESULTS: Among the 138 patients analyzed (95 women, 43 men), the median age was 39 years (IQR, 24-60 years). Technical success was achieved in all cases. During a median follow-up period of 24.4 months, complete tumor disappearance occurred in 67.3% of cases, with T1a tumors showing markedly superior outcomes compared to T1b lesions (82.1% versus 34.8%, P=0.042). Disease progression was observed in 2.9% of patients, including newly detected tumors (1.4%) and lymph node metastasis (1.4%). No local recurrence or distant metastasis was documented. The major complication was transient hoarseness, affecting 10.1% of patients, and all cases resolved spontaneously within six months. Subgroup analysis further identified T1b tumors as an independent risk factor for this complication (P = 0.027). Progression-free survival showed no significant difference between T1a and T1b classifications (P=0.633).
CONCLUSION: MWA offers an effective treatment option for selected patients with BL-adjacent T1N0M0 PTC, achieving favorable local tumor control with acceptable complication rates.